



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

December 2017





HIV/AIDS Drug Treatment Program

Monthly Report

© 2018 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA
CENTRE for EXCELLENCE
in HIV/AIDS



This document is best viewed in colour.
Drug definitions available in the back.



EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

December 2017

N = 7237



Health Authority	Male	Female	All
FRASER	1386	399	1785
INTERIOR	374	96	470
NORTHERN	139	85	224
VANCOUVER COASTAL	3404	446	3850
VANCOUVER ISLAND	725	157	882
	6028	1183	7211
		Unknown/not stated:	26
		Total:	7237

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2012 - December 2017)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2012 - December 2017)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (December 2012 - December 2017)






1.5 BC-CfE Enrollment: New Antiretroviral Participants
(December 2012 - December 2017)






1.6 Percent Distribution of Active Participants by CD4 Count (December 2012 - December 2017)






1.7 Percent Distribution of Inactive Participants by CD4 Count (December 2012 - December 2017)






1.8 Active and Inactive Participants (December 2012 - December 2017)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (December 2012 - December 2017)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (December 2012 - December 2017)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(December 2012 - December 2017)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (December 2012 - December 2017)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(December 2012 - December 2017)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (December 2012 - December 2017)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(December 2012 - December 2017)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (December 2012 - December 2017)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(December 2012 - December 2017)






1.18 Baseline CD4 for Antiretroviral First Starts
(December 2012 - December 2017)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(December 2012 - December 2017)**






1.20 Cumulative Resistance Testing Results by Resistance Category (December 2012 - December 2017)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (December 2012 - December 2017)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2017
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	25	5	0	5	5	720	5	<40	3
1988	27	7	0	7	7	560	7	<40	3
1989	25	56	2	58	46	495	56	<40	3
1990	23	61	1	62	56	525	60	<40	3
1991	24	38	3	41	35	530	40	<40	3
1992	23	66	6	72	57	580	69	<40	3
1993	22	139	16	155	142	570	151	<40	3
1994	21	87	14	101	86	595	95	<40	3
1995	21	132	23	155	128	565	145	<40	3
1996	19	364	55	419	364	590	404	<40	3
1997	17	294	37	331	282	635	307	<40	3
1998	16	206	43	249	212	595	238	<40	3
1999	16	173	43	216	183	560	205	<40	3
2000	17	124	35	159	139	580	151	<40	3
2001	16	129	36	165	137	550	157	<40	3
2002	15	136	28	164	141	600	158	<40	3
2003	14	164	30	194	167	580	185	<40	3
2004	13	174	40	214	177	590	201	<40	3
2005	12	190	45	235	204	610	227	<40	3
2006	11	196	47	243	202	555	224	<40	3
2007	10	268	49	317	262	610	292	<40	3
2008	9	308	69	377	315	630	352	<40	3
2009	8	331	74	405	346	640	386	<40	3
2010	7	290	68	358	297	620	328	<40	3
2011	6	338	74	412	351	670	378	<40	3
2012	5	287	65	352	291	700	327	<40	3
2013	4	278	66	344	280	635	322	<40	3
2014	3	306	54	360	291	680	335	<40	3
2015	3	309	51	360	305	650	340	<40	3
2016	1	302	66	368	307	650	352	<40	3
2017	1	275	43	318	289	540	309	<40	3
Total:		6033	1183	7216					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	6970	735	2262	<40	2024	590
FEB-2016	6989	735	2064	<40	1865	590
MAR-2016	6995	736	2154	<40	1958	590
APR-2016	7014	733	2052	<40	1863	580
MAY-2016	7043	747	2070	<40	1886	590
JUN-2016	7062	739	2179	<40	1993	610
JUL-2016	7052	749	1949	<40	1760	600
AUG-2016	7068	750	2068	<40	1878	590
SEP-2016	7107	751	2214	<40	1998	600
OCT-2016	7138	746	2152	<40	1935	600
NOV-2016	7169	741	2111	<40	1903	580
DEC-2016	7192	748	1871	<40	1709	620
JAN-2017	7182	747	2325	<40	2071	590
FEB-2017	7134	755	1914	<40	1737	590
MAR-2017	7186	745	2203	<40	2017	600
APR-2017	7178	746	1966	<40	1765	590
MAY-2017	7224	744	2276	<40	2056	590
JUN-2017	7246	752	2119	<40	1949	600
JUL-2017	7242	753	1964	<40	1777	580
AUG-2017	7266	757	2105	<40	1868	590
SEP-2017	7224	762	2040	<40	1809	610
OCT-2017	7250	768	2189	<40	1874	610
NOV-2017	7248	766	2076	<40	1795	610
DEC-2017	7237	775	1742	<40	1460	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2016	1518	2305	116	<40	104	465
FEB-2016	1510	2368	83	353	74	380
MAR-2016	1517	2338	87	130	82	430
APR-2016	1521	2326	87	<50	74	360
MAY-2016	1505	2405	79	<40	69	350
JUN-2016	1516	2403	72	76	56	505
JUL-2016	1540	2339	80	51	75	460
AUG-2016	1565	2239	94	158	77	360
SEP-2016	1552	2334	96	240	80	360
OCT-2016	1525	2484	74	<40	69	410
NOV-2016	1522	2533	73	1007	58	380
DEC-2016	1523	2564	52	122	44	480
JAN-2017	1540	2523	88	140	78	417
FEB-2017	1596	2300	79	1387	68	400
MAR-2017	1550	2482	100	568	89	380
APR-2017	1568	2454	94	545	84	420
MAY-2017	1542	2613	86	148	76	420
JUN-2017	1532	2672	76	197	67	490
JUL-2017	1554	2574	69	316	60	515
AUG-2017	1551	2611	78	160	68	495
SEP-2017	1607	2453	75	279	65	420
OCT-2017	1581	2571	89	182	76	485
NOV-2017	1599	2530	78	163	66	350
DEC-2017	1629	2348	59	61	48	380

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2016	6940	1518	9	15	154	168	-11	12422
FEB-2016	6960	1510	5	18	178	163	20	12450
MAR-2016	6968	1517	9	23	171	173	8	12484
APR-2016	6987	1521	6	19	167	157	19	12518
MAY-2016	7018	1505	7	19	163	142	31	12549
JUN-2016	7032	1516	12	34	163	167	14	12592
JUL-2016	7015	1540	11	25	136	157	-17	12624
AUG-2016	7030	1565	10	39	166	173	15	12684
SEP-2016	7072	1552	5	27	179	151	42	12727
OCT-2016	7101	1525	11	22	161	137	29	12758
NOV-2016	7127	1522	20	27	181	160	26	12804
DEC-2016	7149	1523	11	25	154	142	22	12844
JAN-2017	7144	1540	21	21	141	144	-5	12876
FEB-2017	7104	1596	10	24	136	185	-40	12910
MAR-2017	7150	1550	17	19	189	140	46	12936
APR-2017	7141	1568	12	20	143	154	-9	12968
MAY-2017	7194	1542	7	22	170	128	53	13002
JUN-2017	7212	1532	10	24	151	137	18	13032
JUL-2017	7206	1554	7	14	134	144	-6	13051
AUG-2017	7231	1551	10	25	156	141	25	13081
SEP-2017	7189	1607	12	16	137	179	-42	13110
OCT-2017	7222	1581	7	7	185	150	33	13125
NOV-2017	7219	1599	16	20	139	145	-3	13160
DEC-2017	7216	1629	4	19	157	174	-3	13192

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2016	58	6405	446	61	6970	0.83%	91.89%	6.40%	0.88%	100.00%
FEB-2016	59	6436	435	59	6989	0.84%	92.09%	6.22%	0.84%	100.00%
MAR-2016	54	6442	438	61	6995	0.77%	92.09%	6.26%	0.87%	100.00%
APR-2016	54	6464	439	57	7014	0.77%	92.16%	6.26%	0.81%	100.00%
MAY-2016	57	6495	437	54	7043	0.81%	92.22%	6.20%	0.77%	100.00%
JUN-2016	60	6499	447	56	7062	0.85%	92.03%	6.33%	0.79%	100.00%
JUL-2016	57	6496	442	57	7052	0.81%	92.12%	6.27%	0.81%	100.00%
AUG-2016	57	6508	447	56	7068	0.81%	92.08%	6.32%	0.79%	100.00%
SEP-2016	59	6544	447	57	7107	0.83%	92.08%	6.29%	0.80%	100.00%
OCT-2016	84	6556	440	57	7137	1.18%	91.86%	6.17%	0.80%	100.00%
NOV-2016	61	6603	446	59	7169	0.85%	92.10%	6.22%	0.82%	100.00%
DEC-2016	62	6635	437	58	7192	0.86%	92.26%	6.08%	0.81%	100.00%
JAN-2017	61	6615	443	63	7182	0.85%	92.11%	6.17%	0.88%	100.00%
FEB-2017	60	6579	440	55	7134	0.84%	92.22%	6.17%	0.77%	100.00%
MAR-2017	60	6629	439	58	7186	0.83%	92.25%	6.11%	0.81%	100.00%
APR-2017	58	6633	428	59	7178	0.81%	92.41%	5.96%	0.82%	100.00%
MAY-2017	62	6665	438	59	7224	0.86%	92.26%	6.06%	0.82%	100.00%
JUN-2017	57	6691	439	59	7246	0.79%	92.34%	6.06%	0.81%	100.00%
JUL-2017	61	6685	434	62	7242	0.84%	92.31%	5.99%	0.86%	100.00%
AUG-2017	61	6696	448	61	7266	0.84%	92.16%	6.17%	0.84%	100.00%
SEP-2017	57	6679	431	57	7224	0.79%	92.46%	5.97%	0.79%	100.00%
OCT-2017	58	6697	438	57	7250	0.80%	92.37%	6.04%	0.79%	100.00%
NOV-2017	59	6689	444	56	7248	0.81%	92.29%	6.13%	0.77%	100.00%
DEC-2017	59	6675	447	56	7237	0.82%	92.23%	6.18%	0.77%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	4 19%	2818 42%	4 19%	2485 37%	0 0%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	17 81%	4164 62%
FEB-2016	10 36%	2850 42%	9 32%	2518 37%	1 4%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	18 64%	4134 61%
MAR-2016	9 26%	2876 43%	7 21%	2541 38%	1 3%	94 1%	0 0%	11 0%	0 0%	8 0%	0 0%	0 0%	26 76%	4111 61%
APR-2016	12 35%	2893 43%	9 26%	2567 38%	3 9%	93 1%	0 0%	11 0%	0 0%	8 0%	0 0%	5 0%	22 65%	4102 60%
MAY-2016	8 26%	2894 43%	8 26%	2578 38%	0 0%	92 1%	0 0%	11 0%	0 0%	7 0%	0 0%	6 0%	23 74%	4119 61%
JUN-2016	11 26%	2924 43%	11 26%	2602 38%	0 0%	91 1%	0 0%	12 0%	0 0%	7 0%	1 2%	9 0%	31 72%	4116 60%
JUL-2016	9 28%	2903 43%	9 28%	2583 38%	0 0%	90 1%	0 0%	12 0%	0 0%	7 0%	0 0%	9 0%	23 72%	4113 60%
AUG-2016	11 19%	2935 43%	11 19%	2625 38%	0 0%	80 1%	0 0%	11 0%	0 0%	7 0%	6 10%	22 0%	42 71%	4097 60%
SEP-2016	14 33%	2968 43%	12 28%	2658 39%	0 0%	81 1%	0 0%	8 0%	0 0%	6 0%	3 7%	25 0%	27 63%	4101 60%
OCT-2016	11 35%	2997 43%	11 35%	2689 39%	0 0%	82 1%	0 0%	9 0%	0 0%	7 0%	0 0%	26 0%	20 65%	4098 59%
NOV-2016	17 37%	3023 44%	17 37%	2722 39%	0 0%	78 1%	0 0%	7 0%	0 0%	6 0%	0 0%	35 1%	29 63%	4088 59%
DEC-2016	7 18%	3058 44%	7 18%	2753 40%	0 0%	77 1%	0 0%	6 0%	0 0%	6 0%	0 0%	35 1%	33 83%	4077 59%
JAN-2017	13 41%	3068 44%	13 41%	2772 40%	0 0%	75 1%	0 0%	5 0%	0 0%	6 0%	0 0%	46 1%	19 59%	4050 58%
FEB-2017	12 35%	3074 44%	10 29%	2783 40%	1 3%	71 1%	0 0%	5 0%	0 0%	6 0%	0 0%	50 1%	22 65%	3981 58%
MAR-2017	7 27%	3105 45%	7 27%	2824 41%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	0 0%	78 1%	19 73%	4000 57%
APR-2017	13 41%	3114 45%	12 38%	2834 41%	1 3%	68 1%	0 0%	6 0%	0 0%	6 0%	0 0%	96 1%	19 59%	3962 57%
MAY-2017	9 26%	3159 45%	9 26%	2881 41%	0 0%	73 1%	0 0%	6 0%	0 0%	5 0%	1 3%	119 2%	24 71%	3930 56%
JUN-2017	6 20%	3170 45%	6 20%	2903 41%	0 0%	71 1%	0 0%	6 0%	0 0%	5 0%	2 7%	143 2%	22 73%	3898 55%
JUL-2017	7 37%	3199 46%	7 37%	2929 42%	0 0%	72 1%	0 0%	6 0%	0 0%	5 0%	0 0%	161 2%	12 63%	3861 55%
AUG-2017	6 20%	3224 46%	4 13%	2958 42%	0 0%	69 1%	0 0%	6 0%	0 0%	5 0%	2 7%	171 2%	23 77%	3837 54%
SEP-2017	10 34%	3215 46%	10 34%	2952 42%	0 0%	66 1%	0 0%	5 0%	0 0%	4 0%	3 10%	207 3%	16 55%	3774 54%
OCT-2017	6 40%	3245 46%	6 40%	2987 43%	0 0%	65 1%	0 0%	4 0%	0 0%	4 0%	2 13%	245 3%	7 47%	3716 53%
NOV-2017	10 29%	3285 47%	9 26%	3029 43%	0 0%	65 1%	0 0%	5 0%	0 0%	4 0%	1 3%	265 4%	24 69%	3663 52%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2016	17	81%	3848	57%
FEB-2016	18	64%	3828	57%
MAR-2016	25	74%	3809	56%
APR-2016	22	65%	3812	56%
MAY-2016	23	74%	3834	56%
JUN-2016	32	74%	3829	56%
JUL-2016	23	72%	3830	56%
AUG-2016	48	81%	3831	56%
SEP-2016	29	67%	3846	56%
OCT-2016	20	65%	3848	56%
NOV-2016	29	63%	3852	56%
DEC-2016	33	83%	3843	55%
JAN-2017	19	59%	3828	55%
FEB-2017	22	65%	3771	55%
MAR-2017	19	73%	3803	55%
APR-2017	19	59%	3791	55%
MAY-2017	25	74%	3795	54%
JUN-2017	24	80%	3797	54%
JUL-2017	12	63%	3770	54%
AUG-2017	24	80%	3767	53%
SEP-2017	19	66%	3740	53%
OCT-2017	8	53%	3733	53%
NOV-2017	25	71%	3696	53%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2017	9 29%	3291 47%	9 29%	3037 43%	0 0%	64 1%	0 0%	5 0%	0 0%	4 0%	1 3%	272 4%	23 74%	3615 52%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine	
	Initial	All
DEC-2017	22 71%	3669 52%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	0 0%	11 0%	5 45%	1822 55%	5 45%	1127 34%	1 9%	326 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
FEB-2016	0 0%	10 0%	6 46%	1793 55%	6 46%	1154 35%	1 8%	317 10%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAR-2016	0 0%	9 0%	4 25%	1770 55%	11 69%	1170 36%	1 6%	300 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
APR-2016	0 0%	9 0%	1 7%	1747 54%	13 93%	1196 37%	0 0%	293 9%	0 0%	3 0%	0 0%	1 0%	0 0%	17 1%
MAY-2016	0 0%	8 0%	2 17%	1728 53%	10 83%	1219 38%	0 0%	282 9%	0 0%	2 0%	0 0%	1 0%	0 0%	16 0%
JUN-2016	0 0%	8 0%	3 20%	1709 53%	12 80%	1234 38%	0 0%	283 9%	0 0%	4 0%	0 0%	1 0%	0 0%	15 0%
JUL-2016	0 0%	7 0%	3 21%	1689 53%	11 79%	1242 39%	0 0%	273 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
AUG-2016	0 0%	8 0%	3 10%	1663 52%	26 90%	1254 39%	0 0%	268 8%	0 0%	2 0%	0 0%	0 0%	0 0%	14 0%
SEP-2016	0 0%	8 0%	1 9%	1643 52%	9 82%	1269 40%	1 9%	262 8%	0 0%	3 0%	0 0%	1 0%	0 0%	14 0%
OCT-2016	0 0%	8 0%	2 18%	1615 51%	9 82%	1263 40%	0 0%	261 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
NOV-2016	0 0%	9 0%	3 16%	1588 51%	15 79%	1282 41%	1 5%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
DEC-2016	0 0%	9 0%	3 17%	1588 50%	15 83%	1305 41%	0 0%	258 8%	0 0%	3 0%	0 0%	1 0%	0 0%	13 0%
JAN-2017	0 0%	9 0%	2 14%	1558 50%	12 86%	1312 42%	0 0%	247 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
FEB-2017	0 0%	9 0%	3 19%	1518 49%	12 75%	1306 43%	1 6%	236 8%	0 0%	3 0%	0 0%	1 0%	0 0%	12 0%
MAR-2017	0 0%	8 0%	1 8%	1513 49%	11 92%	1329 43%	0 0%	232 8%	0 0%	2 0%	0 0%	1 0%	0 0%	12 0%
APR-2017	0 0%	8 0%	0 0%	1484 49%	5 71%	1318 43%	2 29%	231 8%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2017	0 0%	9 0%	0 0%	1462 48%	14 100%	1350 44%	0 0%	227 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUN-2017	0 0%	9 0%	2 18%	1453 48%	9 82%	1360 45%	0 0%	221 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
JUL-2017	0 0%	9 0%	0 0%	1439 47%	6 100%	1360 45%	0 0%	218 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
AUG-2017	0 0%	9 0%	1 5%	1417 47%	21 95%	1395 46%	0 0%	216 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
SEP-2017	0 0%	9 0%	0 0%	1388 46%	8 100%	1388 46%	0 0%	210 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
OCT-2017	0 0%	8 0%	0 0%	1365 46%	6 100%	1395 47%	0 0%	207 7%	0 0%	3 0%	0 0%	1 0%	0 0%	11 0%
NOV-2017	0 0%	8 0%	1 8%	1326 45%	10 83%	1390 47%	1 8%	206 7%	0 0%	3 0%	0 0%	1 0%	0 0%	10 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2016	0	0%	1	0%
FEB-2016	0	0%	1	0%
MAR-2016	0	0%	1	0%
APR-2016	0	0%	1	0%
MAY-2016	0	0%	1	0%
JUN-2016	0	0%	1	0%
JUL-2016	0	0%	1	0%
AUG-2016	0	0%	0	0%
SEP-2016	0	0%	1	0%
OCT-2016	0	0%	1	0%
NOV-2016	0	0%	1	0%
DEC-2016	0	0%	1	0%
JAN-2017	0	0%	1	0%
FEB-2017	0	0%	1	0%
MAR-2017	0	0%	1	0%
APR-2017	0	0%	1	0%
MAY-2017	0	0%	1	0%
JUN-2017	0	0%	1	0%
JUL-2017	0	0%	1	0%
AUG-2017	0	0%	1	0%
SEP-2017	0	0%	1	0%
OCT-2017	0	0%	1	0%
NOV-2017	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	(fos)amprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2017	0 0%	7 0%	1 7%	1296 45%	14 93%	1398 48%	0 0%	197 7%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
DEC-2017	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	2 100%	1032 42%	0 0%	302 12%	0 0%	855 35%	0 0%	256 10%
FEB-2016	3 60%	1008 41%	0 0%	306 13%	1 20%	857 35%	1 20%	259 11%
MAR-2016	2 50%	996 41%	0 0%	307 13%	1 25%	854 35%	1 25%	257 11%
APR-2016	3 33%	990 41%	1 11%	308 13%	3 33%	845 35%	2 22%	260 11%
MAY-2016	5 63%	986 41%	0 0%	303 13%	0 0%	834 35%	3 38%	260 11%
JUN-2016	4 67%	979 41%	0 0%	298 13%	0 0%	839 35%	2 33%	260 11%
JUL-2016	1 25%	969 41%	1 25%	299 13%	2 50%	836 35%	0 0%	257 11%
AUG-2016	5 71%	960 41%	0 0%	295 13%	0 0%	830 35%	2 29%	262 11%
SEP-2016	2 50%	949 41%	0 0%	295 13%	0 0%	819 35%	2 50%	265 11%
OCT-2016	1 20%	944 41%	2 40%	300 13%	1 20%	814 35%	1 20%	269 12%
NOV-2016	7 88%	936 41%	1 13%	294 13%	0 0%	812 35%	0 0%	269 12%
DEC-2016	7 70%	927 40%	0 0%	290 13%	0 0%	805 35%	3 30%	273 12%
JAN-2017	4 80%	928 41%	0 0%	292 13%	1 20%	799 35%	0 0%	269 12%
FEB-2017	4 80%	907 40%	0 0%	280 12%	0 0%	791 35%	1 20%	266 12%
MAR-2017	1 50%	897 40%	0 0%	279 13%	0 0%	790 35%	1 50%	265 12%
APR-2017	4 44%	888 40%	0 0%	273 12%	1 11%	787 36%	4 44%	271 12%
MAY-2017	3 75%	877 40%	0 0%	274 12%	0 0%	783 35%	1 25%	279 13%
JUN-2017	3 100%	853 39%	0 0%	270 12%	0 0%	782 36%	0 0%	288 13%
JUL-2017	2 100%	838 39%	0 0%	264 12%	0 0%	779 36%	0 0%	283 13%
AUG-2017	1 100%	821 38%	0 0%	268 12%	0 0%	777 36%	0 0%	285 13%
SEP-2017	4 50%	808 38%	0 0%	264 12%	1 13%	774 36%	3 38%	296 14%
OCT-2017	2 100%	803 38%	0 0%	267 13%	0 0%	768 36%	0 0%	299 14%
NOV-2017	4 67%	800 38%	0 0%	269 13%	0 0%	767 36%	2 33%	300 14%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.8 Number of Participants on Non-Nucleosides by INGREDIENT (continued)

	efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2017	3 75%	793 38%	0 0%	263 12%	0 0%	759 36%	1 25%	301 14%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2016	6 55%	1020 44%	4 36%	458 20%	0 0%	66 3%	1 9%	821 35%	0 0%	1 0%
FEB-2016	7 64%	1062 45%	4 36%	468 20%	0 0%	60 3%	0 0%	813 34%	0 0%	1 0%
MAR-2016	15 79%	1115 46%	2 11%	482 20%	0 0%	60 2%	2 11%	806 33%	0 0%	1 0%
APR-2016	12 67%	1153 47%	4 22%	491 20%	0 0%	60 2%	2 11%	799 32%	0 0%	1 0%
MAY-2016	13 76%	1182 47%	4 24%	493 20%	0 0%	60 2%	0 0%	798 32%	0 0%	1 0%
JUN-2016	16 62%	1216 48%	9 35%	506 20%	0 0%	58 2%	1 4%	788 31%	0 0%	1 0%
JUL-2016	14 70%	1251 49%	5 25%	517 20%	0 0%	57 2%	1 5%	784 30%	0 0%	1 0%
AUG-2016	20 59%	1304 49%	14 41%	533 20%	0 0%	55 2%	0 0%	774 29%	0 0%	1 0%
SEP-2016	19 63%	1363 50%	10 33%	545 20%	0 0%	53 2%	1 3%	781 29%	0 0%	1 0%
OCT-2016	15 94%	1412 51%	1 6%	561 20%	0 0%	53 2%	0 0%	777 28%	0 0%	1 0%
NOV-2016	18 72%	1452 52%	5 20%	580 21%	0 0%	53 2%	2 8%	756 27%	0 0%	1 0%
DEC-2016	9 75%	1479 52%	2 17%	587 21%	0 0%	53 2%	1 8%	762 27%	0 0%	1 0%
JAN-2017	13 81%	1518 53%	3 19%	587 20%	0 0%	52 2%	0 0%	756 26%	0 0%	1 0%
FEB-2017	14 78%	1560 54%	4 22%	588 20%	0 0%	48 2%	0 0%	732 25%	0 0%	1 0%
MAR-2017	13 87%	1620 55%	2 13%	601 20%	0 0%	49 2%	0 0%	732 25%	0 0%	1 0%
APR-2017	14 78%	1655 55%	4 22%	596 20%	0 0%	50 2%	0 0%	722 24%	0 0%	1 0%
MAY-2017	19 86%	1726 57%	3 14%	602 20%	0 0%	47 2%	0 0%	715 23%	0 0%	1 0%
JUN-2017	12 75%	1758 57%	3 19%	596 19%	0 0%	49 2%	1 6%	713 23%	0 0%	1 0%
JUL-2017	8 73%	1792 58%	3 27%	592 19%	0 0%	48 2%	0 0%	705 23%	0 0%	1 0%
AUG-2017	13 72%	1824 58%	4 22%	596 19%	0 0%	49 2%	1 6%	707 22%	0 0%	1 0%
SEP-2017	10 71%	1835 58%	4 29%	600 19%	0 0%	50 2%	0 0%	700 22%	0 0%	1 0%
OCT-2017	9 90%	1883 59%	1 10%	609 19%	0 0%	48 1%	0 0%	707 22%	0 0%	0 0%
NOV-2017	15 68%	1943 60%	5 23%	613 19%	0 0%	49 2%	2 9%	700 21%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT (continued)

	dolutegravir		elvitegravir		maraviroc		raltegravir		enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
DEC-2017	11 65%	1962 60%	6 35%	606 19%	0 0%	48 1%	0 0%	688 21%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2016	2285	32.78	1944	27.89	1609	23.08	158	2.27	61	0.88	913	13.10
FEB-2016	2279	32.61	1925	27.54	1668	23.87	153	2.19	59	0.84	905	12.95
MAR-2016	2266	32.39	1903	27.21	1706	24.39	154	2.20	61	0.87	905	12.94
APR-2016	2244	31.99	1894	27.00	1757	25.05	154	2.20	57	0.81	908	12.95
MAY-2016	2256	32.03	1887	26.79	1781	25.29	157	2.23	54	0.77	908	12.89
JUN-2016	2255	31.93	1877	26.58	1811	25.64	152	2.15	56	0.79	911	12.90
JUL-2016	2225	31.55	1865	26.45	1847	26.19	150	2.13	57	0.81	908	12.88
AUG-2016	2210	31.27	1839	26.02	1912	27.05	142	2.01	56	0.79	909	12.86
SEP-2016	2190	30.81	1831	25.76	1976	27.80	144	2.03	57	0.80	909	12.79
OCT-2016	2156	30.21	1828	25.61	2026	28.39	148	2.07	57	0.80	922	12.92
NOV-2016	2174	30.33	1817	25.35	2074	28.93	143	1.99	59	0.82	902	12.58
DEC-2016	2181	30.33	1808	25.14	2102	29.23	143	1.99	58	0.81	900	12.51
JAN-2017	2155	30.01	1793	24.97	2135	29.73	139	1.94	63	0.88	897	12.49
FEB-2017	2125	29.79	1772	24.84	2165	30.35	133	1.86	55	0.77	884	12.39
MAR-2017	2133	29.68	1754	24.41	2223	30.94	134	1.86	58	0.81	884	12.30
APR-2017	2109	29.38	1744	24.30	2260	31.49	133	1.85	59	0.82	873	12.16
MAY-2017	2108	29.18	1737	24.04	2308	31.95	132	1.83	59	0.82	880	12.18
JUN-2017	2115	29.19	1719	23.72	2349	32.42	132	1.82	59	0.81	872	12.03
JUL-2017	2102	29.03	1694	23.39	2386	32.95	130	1.80	62	0.86	868	11.99
AUG-2017	2094	28.82	1687	23.22	2408	33.14	130	1.79	61	0.84	886	12.19
SEP-2017	2074	28.71	1676	23.20	2429	33.62	127	1.76	57	0.79	861	11.92
OCT-2017	2051	28.29	1675	23.10	2480	34.21	124	1.71	57	0.79	863	11.90
NOV-2017	2006	27.68	1668	23.01	2525	34.84	119	1.64	56	0.77	874	12.06
DEC-2017	2000	27.64	1661	22.95	2537	35.06	115	1.59	56	0.77	868	11.99

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2016	15	2	3	0	4	3	379
FEB-2016	18	4	0	6	3	5	331
MAR-2016	23	4	3	4	7	5	350
APR-2016	19	2	1	2	2	8	600
MAY-2016	19	2	1	3	3	10	509
JUN-2016	34	5	5	6	10	8	380
JUL-2016	25	2	6	6	3	7	320
AUG-2016	39	2	6	6	12	13	410
SEP-2016	27	8	2	6	4	4	253
OCT-2016	22	2	2	6	6	5	370
NOV-2016	27	3	4	5	7	8	390
DEC-2016	25	4	1	5	3	11	410
JAN-2017	21	3	2	3	6	6	390
FEB-2017	24	5	3	1	3	10	425
MAR-2017	19	5	3	5	2	2	220
APR-2017	20	1	2	6	5	5	350
MAY-2017	22	2	0	3	9	8	405
JUN-2017	24	6	2	5	3	7	230
JUL-2017	14	2	2	2	1	5	340
AUG-2017	25	4	0	4	3	12	510
SEP-2017	16	1	2	3	3	5	440
OCT-2017	7	2	0	0	1	3	545
NOV-2017	20	2	2	6	3	7	385
DEC-2017	19	2	2	4	4	6	405

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2016	11042	3047
FEB-2016	11135	3128
MAR-2016	11194	3175
APR-2016	11241	3209
MAY-2016	11301	3258
JUN-2016	11356	3288
JUL-2016	11399	3323
AUG-2016	11444	3329
SEP-2016	11470	3332
OCT-2016	11501	3356
NOV-2016	11543	3377
DEC-2016	11573	3388
JAN-2017	11592	3407
FEB-2017	11619	3416
MAR-2017	11669	3465
APR-2017	11695	3480
MAY-2017	11736	3505
JUN-2017	11765	3521
JUL-2017	11798	3552
AUG-2017	11833	3578
SEP-2017	11860	3603
OCT-2017	11918	3655
NOV-2017	11931	3655
DEC-2017	11959	3660

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
December 2017

N = 7237

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2017

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2017

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2017

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2017

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	34	47	25
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	72	94	52	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	350	467	260	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	17
	35-49	*	*	43
	50+	*	*	73
Total HSDA:	178	237	133	
Total HA:		634	845	470

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		634	845	470

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	494	670	374
Female	140	175	96

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	470	54	600	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	5	5
	<5 years	11	9
	Total HSDA:	34	25
KOOTENAY BOUNDARY	10 years or more	38	26
	5 years or more	21	15
	<5 years	13	11
	Total HSDA:	72	52
OKANAGAN	10 years or more	201	139
	5 years or more	75	61
	<5 years	74	60
	Total HSDA:	350	260
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	88	57
	5 years or more	40	37
	<5 years	50	39
	Total HSDA:	178	133
Total HA:		634	470

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	345	233
5 years or more	141	118
<5 years	148	119
Total HA:	634	470

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	38	55	14	23
KOOTENAY BOUNDARY	63	115	21	41
OKANAGAN	204	760	67	274
THOMPSON/CARIBOO/SHUSWAP	127	460	36	121
Total:	432	1390	138	459

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	0
KOOTENAY BOUNDARY	10
OKANAGAN	43
THOMPSON/CARIBOO/SHUSWAP	34
Total:	87

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	5
	20-34	27	28	18
	35-49	107	119	74
	50+	201	269	161
	Total HSDA:	341	422	258
FRASER NORTH	0-19	13	13	*
	20-34	111	112	*
	35-49	350	391	*
	50+	509	803	*
	Total HSDA:	983	1319	769
FRASER SOUTH	0-19	9	9	6
	20-34	97	99	71
	35-49	361	411	290
	50+	473	697	391
	Total HSDA:	940	1216	758
Total HA:		2264	2957	1785

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	28	28	14
	20-34	235	239	176
	35-49	818	921	633
	50+	1183	1769	962
Total HA:		2264	2957	1785

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1724	2280	1386
Female	540	677	399

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1785	51	610	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	174	126
	5 years or more	95	77
	<5 years	72	55
	Total HSDA:	341	258
FRASER NORTH	10 years or more	489	354
	5 years or more	253	199
	<5 years	241	216
	Total HSDA:	983	769
FRASER SOUTH	10 years or more	463	365
	5 years or more	242	191
	<5 years	235	202
	Total HSDA:	940	758
Total HA:		2264	1785

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1126	845
	5 years or more	590	467
	<5 years	548	473
Total HA:		2264	1785

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	134	455	39	87
FRASER NORTH	238	1503	54	254
FRASER SOUTH	205	1251	43	350
Total:	577	3209	136	691

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	191
FRASER NORTH	659
FRASER SOUTH	519
Total:	1369

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	24
	35-49	*	*	63
	50+	*	*	190
	Total HSDA:		321	462
RICHMOND	0-19	*	*	0
	20-34	*	*	16
	35-49	*	*	31
	50+	*	*	77
	Total HSDA:		160	206
VANCOUVER	0-19	41	44	5
	20-34	442	453	328
	35-49	1492	1692	1085
	50+	2639	4441	2031
	Total HSDA:	4614	6630	3449
Total HA:		5095	7298	3850

Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
0-19	45	48	5
20-34	491	503	368
35-49	1613	1829	1179
50+	2946	4918	2298
Total HA:	5095	7298	3850

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	4477	6408	3404
Female	616	888	446

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3850	52	620	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	167	136
	5 years or more	80	71
	<5 years	74	70
	Total HSDA:	321	277
RICHMOND	10 years or more	81	58
	5 years or more	42	34
	<5 years	37	32
	Total HSDA:	160	124
VANCOUVER	10 years or more	2498	1795
	5 years or more	1210	908
	<5 years	906	746
	Never on ART	0	0
	Total HSDA:	4614	3449
Total HA:	5095	3850	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2746	1989
5 years or more	1332	1013
<5 years	1017	848
Never on ART	0	0
Total HA:	5095	3850

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	155	401	55	109
RICHMOND	42	275	13	93
VANCOUVER	561	10383	202	5384
Total:	758	11059	270	5586

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	144

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		308	428
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		119	156
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		696	976
Total HA:		1123	1560	882

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	5
	20-34	100	106	73
	35-49	315	361	244
	50+	699	1084	560
Total HA:		1123	1560	882

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	917	1275	725
Female	206	285	157

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	882	53	520	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	146	119
	5 years or more	73	59
	<5 years	89	74
	Total HSDA:	308	252
NORTH VANCOUVER ISLAND	10 years or more	62	50
	5 years or more	27	22
	<5 years	30	23
	Total HSDA:	119	95
SOUTH VANCOUVER ISLAND	10 years or more	373	269
	5 years or more	158	129
	<5 years	165	137
	Total HSDA:	696	535
Total HA:		1123	882

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	581	438
	5 years or more	258	210
	<5 years	284	234
Total HA:		1123	882

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	183	814	81	216
NORTH VANCOUVER ISLAND	126	253	45	78
SOUTH VANCOUVER ISLAND	196	1651	43	543
Total:	505	2718	169	837

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	45
NORTH VANCOUVER ISLAND	31
SOUTH VANCOUVER ISLAND	106
Total:	182

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	0-19	*	*	0
	20-34	*	*	6
	35-49	*	*	18
	50+	*	*	29
	Total HSDA:		69	105
NORTHERN INTERIOR	0-19	6	6	*
	20-34	24	27	*
	35-49	74	91	*
	50+	85	136	*
	Total HSDA:		189	260
Total HA:		298	413	224

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	9	9	*
	20-34	36	40	*
	35-49	111	147	*
	50+	142	217	*
Total HA:		298	413	224

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	181	256	139
Female	117	157	85

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	224	50	515	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	17	9
	5 years or more	14	8
	<5 years	9	7
	Total HSDA:	40	24
NORTH WEST	10 years or more	23	13
	5 years or more	31	28
	<5 years	15	12
	Total HSDA:	69	53
NORTHERN INTERIOR	10 years or more	63	41
	5 years or more	67	59
	<5 years	59	47
	Total HSDA:	189	147
Total HA:		298	224

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	103	63
	5 years or more	112	95
	<5 years	83	66
Total HA:		298	224

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	35	60	8	10
NORTH WEST	67	151	17	28
NORTHERN INTERIOR	103	422	15	181
Total:	205	633	40	219

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	13
NORTHERN INTERIOR	22
Total:	42

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	7	*
	OKANAGAN	*	33	*
	THOMPSON/CARIBOO/SHUSWAP	*	40	*
	Total HA:	51	90	36
FRASER	FRASER EAST	33	42	23
	FRASER NORTH	50	83	43
	FRASER SOUTH	73	103	57
	Total HA:	156	228	123
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	47	23
	RICHMOND	10	15	8
	VANCOUVER	516	837	414
	Total HA:	552	899	445
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	50	76	43
	NORTH VANCOUVER ISLAND	16	25	14
	SOUTH VANCOUVER ISLAND	34	74	27
	Total HA:	100	175	84
NORTHERN	NORTH EAST	9	11	7
	NORTH WEST	32	59	27
	NORTHERN INTERIOR	68	101	62
	Total HA:	109	171	96
Total:		968	1563	784

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	600	998	481
Female	368	565	303

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	784	50	470	35

* Patients numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicstat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicstat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Delavirdine (Rescriptor, DLV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from ViiV Healthcare.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Indinavir (Crixivan, IDV): a PROTEASE INHIBITOR from Merck.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

